首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >IFN-beta-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
【24h】

IFN-beta-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.

机译:干扰素-β调节的基因在未经治疗的复发-复发性MS单核细胞中显示异常表达:采用所有报道的蛋白质-蛋白质相互作用的基因表达分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The molecular mechanism by which interferon beta (IFN-beta) is effective in treating multiple sclerosis is not well understood. Mononuclear cells from therapy-naive MS patients, IFN-beta-1b-treated MS patients, and healthy controls were analyzed to examine mRNA changes that characterize both the disease and its treatment. The scientific literature was comprehensively searched for all protein-protein interactions. In MS patients who had never been treated with IFN-beta, statistical analysis revealed coordinate changes in mRNA expression for proteins reported in the literature as "regulated by IFN-beta." As a positive control for this approach, samples from a separate MS patient cohort showed significant change of these same genes during in vivo treatment with IFN-beta-1b.The strength of effect observed for regulation by IFN-beta was greater than for IFN-alpha, IFN-gamma (Th1), or IL-4 (Th2). Of the sets we investigated, the most strongly affected by disease was the subset defined by regulation by both IFN-beta and IFN-alpha. Changes in cells from therapy-naive MS patients thus anticipated the importance of IFN-beta in therapy. These findings are a significant step towards marrying MS disease etiology and IFN-beta mechanism of action at a molecular level.
机译:干扰素β(IFN-β)有效治疗多发性硬化症的分子机制尚不清楚。对未接受过治疗的MS患者,接受IFN-β-1b治疗的MS患者以及健康对照的单核细胞进行了分析,以检查表征该疾病及其治疗方法的mRNA变化。在科学文献中全面搜索了所有蛋白质-蛋白质相互作用。在从未接受过IFN-β治疗的MS患者中,统计分析显示,文献中报道的蛋白质的mRNA表达的坐标变化为“受IFN-β调节”。作为该方法的阳性对照,来自一个单独的MS患者队列的样品在用IFN-beta-1b进行体内治疗期间显示出这些相同基因的显着变化。观察到的通过IFN-beta进行调节的作用强​​度要强于对IFN-beta的调节作用。 α,IFN-γ(Th1)或IL-4(Th2)。在我们研究的组中,受疾病影响最大的是由IFN-beta和IFN-alpha共同调节的子集。因此,未经治疗的MS患者的细胞变化预示着IFN-β在治疗中的重要性。这些发现是在分子水平上将MS疾病病因学和IFN-β作用机制结合起来的重要一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号